Docetaxel chemotherapy linked to rare heart attack in breast cancer patient

A patient with triple-negative breast cancer received docetaxel chemotherapy. Shortly after treatment, she suffered an acute ST-segment elevation myocardial infarction. This event is a serious heart attack that blocks blood flow to the heart muscle. Doctors reviewed this single case along with twelve other published reports and data from a safety database. They found nine other similar instances linked to docetaxel exposure. The evidence points to a direct link between the drug and these heart attacks. The exact pathway remains unclear, but it may involve coronary vasospasm, endothelial dysfunction, or prothrombotic effects. These terms describe tight blood vessel squeezing, lining damage, or increased clotting risk. Because the mechanism is not fully understood, caution is needed. The patient stopped her subsequent docetaxel regimen after this event. This review highlights the importance of proper cardiac management even in patients assessed as low-risk for cardiotoxicity. No relevant cardiovascular factors were present in this specific case. While rare, these events show that patients need monitoring during treatment.